About the Company
paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRTK News
ArriVent Appoints Kristine Peterson to its Board of Directors
“I am excited to work alongside ArriVent’s talented management team and Board of Directors to help address the unmet needs of cancer patients,” said Ms. Peterson. “I look forward to providing ...
Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline Momentum
Clarametyx expands its team with experts in corporate and clinical development to accelerate progress with its anti-biofilm platform.
Acute Bacterial Skin & Skin Structure Infections Treatment Market hit 9.6% CAGR
According to Market.us, the anticipated value of the global acute bacterial skin and skin structure infections treatment ...
Oric Pharmaceuticals presents new PLK4 inhibitors
Oric Pharmaceuticals Inc. has divulged serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.
Loading the latest forecasts...